Merck & Co. Total Current Liabilities decreased by 4.9% to $26.95B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.0%, from $25.17B to $26.95B. Over 5 years (FY 2020 to FY 2025), Total Current Liabilities shows relatively stable performance with a 0.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A high ratio of current liabilities to current assets may signal liquidity stress, whereas a lower ratio suggests a stronger ability to cover short-term debts.
This is the sum of all financial obligations due within one year, including accounts payable, short-term debt, and accru...
Healthy companies generally maintain a current ratio (current assets/current liabilities) above 1.0, though this varies by industry.
total_current_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $21.91B | $23.73B | $23.87B | $22.32B | $23.17B | $23.00B | $24.24B | $23.13B | $23.39B | $23.09B | $25.69B | $25.10B | $26.06B | $29.59B | $28.42B | $25.17B | $26.04B | $28.63B | $28.33B | $26.95B |
| QoQ Change | — | +8.3% | +0.6% | -6.5% | +3.8% | -0.7% | +5.4% | -4.6% | +1.1% | -1.3% | +11.3% | -2.3% | +3.8% | +13.5% | -3.9% | -11.4% | +3.4% | +10.0% | -1.1% | -4.9% |
| YoY Change | — | — | — | — | +5.8% | -3.1% | +1.5% | +3.7% | +1.0% | +0.4% | +6.0% | +8.5% | +11.4% | +28.1% | +10.6% | +0.3% | -0.1% | -3.2% | -0.3% | +7.0% |